Big Pharma Payday: US Government to Purchase $1 Billion More in Merck’s COVID-19 Pill
A recent international report of 64 studies shows Ivermectin has an 86% success rate as a prophylaxis and a 67% success rate in early treatment of coronavirus.
The results mirror the over 290 studies on hydroxychloroquine that have been reported over the past year.
The CDC, Dr. Fauci and the FDA ridiculed the use of the drugs to treat the China Virus despite their continued effectiveness in peer-reviewed studies.
The Gateway Pundit has reported extensively on the CDC’s decisions that resulted in the deaths of thousands of Americans.
Now, as the vaccines continue to fail the US government is purchasing one billion dollars worth of the expensive treatment drug molnupiravir — similar to HCQ and Ivermectin but more expensive — from Merck and Co.
